Volume 1.05 | Feb 12

Prostate Cell News 1.05, February 12, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Identification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft Model
Findings reveal that EP4 overexpression, via androgen receptor activation, supports an important mechanism for castration-resistant progression of prostate cancer. [Cancer Res]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies



Using Nitroglycerin to Treat Prostate Cancer Shows Potential to Halt Disease
Treatment of prostate cancer using a very low dose of nitroglycerin may slow and even halt the progression of the disease without the severe side effects of current treatments. [Press release from ScienceDaily discussing online prepublication in Urology]

Lower Detection of Prostate Cancer with Prostate-Specific Antigen Screening in U.S. Than in a European Randomized Trial
Fewer prostate cancers were detected by prostate-specific antigen screening in the U.S. than in a European randomized trial because of lower screening sensitivity. [Press release from ScienceDaily discussing online prepublication in the Journal of the National Cancer Institute]

Loyola Study Points to Possible Novel Approach to Treating Breast Cancer, Prostate Cancer, Enlarged Hearts and Carney Complex
In a new approach to developing treatments for breast cancer, prostate cancer and enlarged hearts, researchers are zeroing in on a workhorse protein called RSK. [Press release from Loyola University Stritch School of Medicine discussing online prepublication in the Journal of Biological Chemistry]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies





Long-Range Enhancers on 8q24 Regulate c-Myc
Here, researchers show that multiple enhancer elements are present within the region of chromosome 8q24 and that they can regulate transcription of Myc. In addition, the enhancer element physically interacts with the Myc promoter via transcription factor Tcf-4 binding and acts in an allele specific manner to regulate Myc expression. [Proc Natl Acad Sci U S A]

Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice
Results suggest that control of locally advanced human prostate cancer may be achievable through intraprostatic injection and amplification of a safe oncolytic virus, such as VSV(AV3). [Cancer Res]

Prosaposin Down-Modulation Decreases Metastatic Prostate Cancer Cell Adhesion, Migration, and Invasion
Findings suggest that by a coordinated regulation of ceramide levels, cathepsin D and beta1A-integrin expression, and attenuation of “inside-out” integrin-signaling pathway, prosaposin is involved in prostate cancer invasion and therefore might be used as a molecular target for prostate cancer therapy. [Mol Cancer]

Pim1 Kinase Synergizes with c-Myc to Induce Advanced Prostate Carcinoma
Results directly show functional cooperativity between c-Myc and PIM1 in prostate tumorigenesis in vivo and support efforts for targeting PIM1 in prostate cancer. [Oncogene

Low Levels of Phosphorylated Epidermal Growth Factor Receptor (pEGFR) in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
Low pEGFR immunoreactivity is associated with the favorable prognosis in prostate cancer patients and may provide information about which patients with Gleason score 6 and 7 tumors that will survive their disease even without treatment. Changes in the nonmalignant tissue adjacent to prostate tumors give prognostic information. [Clin Cancer Res]

The Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-Regulation of the Alzheimer Amyloid Precursor Protein
The data suggest that beta-amyloid precursor protein down-regulation via histone deacetylase inhibition provides a novel mechanism for pancreatic and colon cancer therapy. [J Biol Chem]

GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
Results suggest that the activation of GAS6 receptors on prostate cancer in the marrow environment may play a critical role as a molecular switch to establish dormancy. [Neoplasia]

Beta-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor
Here researchers show that beta-TrCP depletion suppresses prostate cancer and identify a relevant growth control mechanism. shRNA targeted against beta-TrCP reduced prostate cancer cell growth and cooperated with androgen ablation in vitro and in vivo. [PLoS One]


Prostate-Specific Antigen Screening in the United States versus in the European Randomized Study of Screening for Prostate Cancer-Rotterdam
Researchers conclude that the efficacy of prostate-specific antigen screening in detecting prostate cancer was lower in the United States than in the European Randomized Study of Screening for Prostate Cancer -Rotterdam. [J Natl Cancer Inst]
Phase I/II Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer
Preoperative chemotherapy with docetaxel and mitoxantrone is feasible. Approximately half of the high-risk patients remain free of disease recurrence at 5 years, and clinical and molecular predictors of early recurrence were identified. [Cancer]



Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase III Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Amgen announced that a pivotal, Phase III, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. [Amgen Press Release]

Patient Access Network Opens 5 New Funds Including Prostate Cancer
Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds — including grants of up to $10,000 per year for prostate cancer patients. [PR Newswire]



Senate Rejects Stem Cell Legislation
By a vote of 21 to 12, the South Dakota Senate shot down a bill that could have repealed South Dakota’s ban on embryonic stem cell treatments. [South Dakota Senate, United States]

Parsing National Institutes of Health’s 2011 Budget: Is Big Science Up, Small Science Down?
Is National Institutes of Health Director Francis Collins planning to steer his ocean liner of an institute toward “big biology” at the expense of single-investigator grants? [National Institutes of Health, United States]

Medvedev Talks Science in Moscow
Russian science has been getting some bad press recently, what with a recent report on its declining productivity in scientific papers and a letter from expatriate scientists to the Russian president and prime minister warning of the parlous state of basic research. [Russian Academy of Sciences, Russia]

Impersonation of MHRA Staff [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Waivers for Conflicts of Interest for the February 22, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Center for Biologics Evaluation and Research, United States]
Recovery Act Limited Competition: Program to Enhance National Institutes of Health-Supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001) [National Institutes of Health, United States]

IACUC 101 Workshop and PRIM&R 2010 IACUC Conference: March 21-23, 2010 in Baltimore, MD (NOT-OD-10-059) [National Institutes of Health, United States]

Delays in Grant Application Submission Due to Blizzard (NOT-OD-10-060) [National Institutes of Health, United States]

Notice of Intent to Establish a New National Institutes of Health Common Fund Program: Library of Integrated Network-Based Cellular Signatures (LINCS) (NOT-RM-10-002) [National Institutes of Health, United States]
Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Heart, Lung, and Blood Institute, United States]




SMi’s Second Annual Stem Cells 2010
February 15-16, 2010
London, United Kingdom

Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
February 15-20, 2010
Keystone, United States

5th Annual Stem Cell Summit
February 16, 2010
New York, United States

Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
February 24-27, 2010
Washington, DC, United States

The 3rd World Congress on Controversies in Urology (CURy)
February 25-28, 2010
Athens, Greece

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research (AACR) 101st Annual Meeting
April 17-21, 2010
Washington, DC, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



Business Development Europe – Cell Therapy Products (PALL Corporation)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here  to post your career opportunities.



Have we missed an important article or publication in Prostate Cell News? Click here to submit!


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us